24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice

被引:251
作者
Fickert, P
Wagner, M
Marschall, HU
Fuchsbichler, A
Zollner, G
Tsybrovskyy, O
Zatloukal, K
Liu, J
Waalkes, MP
Cover, C
Denk, H
Hofman, AF
Jaeschke, H
Trauner, M
机构
[1] Med Univ Graz, Dept Med, Div Gastroenterol & Hepatol, Lab Expt & Mol Hepatol, A-8036 Graz, Austria
[2] Med Univ Graz, Inst Pathol, A-8036 Graz, Austria
[3] Karolinska Univ Hosp, Stockholm, Sweden
[4] NCI, Comparat Carcinogenesis Lab, NIEHS, Res Triangle Pk, NC USA
[5] Univ Arizona, Liver Res Inst, Tucson, AZ USA
[6] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
基金
奥地利科学基金会;
关键词
D O I
10.1053/j.gastro.2005.10.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Current therapy for primary sclerosing cholangitis is of limited efficacy. Multidrug resistance gene 2 knockout mice (Mdr2(-/-)) represent a well-characterized model for sclerosing cholangitis. Experiments were performed to test in such mice the therapeutic effects of 24-norUrsodeoxycholic acid, a C-23 homologue of ursodeoxycholic acid with I fewer methylene group in its side chain. Methods: Mdr2(-/-) mice were fed a diet containing 24-norUrsodeoxycholic acid (0.5% wt/wt) or ursodeoxycholic acid (0.5% wt/wt) as a clinical comparator for 4 weeks; controls received standard chow. Effects on serum liver tests, liver histology, markers of inflammation and fibrosis, and bile acid transport and metabolism were compared. 24-norUr-socleoxycholic acid metabolism was studied in serum, liver, bile, and urine. Results: 24-norUrsodeoxycholic acid markedly improved liver tests and liver histology and significantly reduced hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes. 24-norUrsodeoxycholic acid underwent extensive phase I/II metabolism (hydroxylation, sulfation, and glucuronidation), thereby increasing the hydrophilicity of biliary bile acid secretion. There was a coordinated induction of bile acid detoxifying enzymes (Cyp2b:10, Cyp3a11, and Sult2a1) and efflux pumps (Mrp3 and Mrp4). Ursodeoxycholic acid, in contrast, increased alanine transaminase and alkaline phosphatase levels, had no significant effects on hydroxyproline content, and induced biliary transporters and detoxification enzymes to a much smaller extent than 24-norUrsodeoxycholic acid. Conclusions: 24-norUrsodeoxycholic acid ameliorates sclerosing cholangitis in Mdr2(-/-) mice. Its therapeutic mechanisms involve (1) increasing the hydrophilicity of biliary bile acids, (2) stimulating bile flow with flushing of injured bile ducts, and (3) inducing detoxification and elimination routes for bile acids.
引用
收藏
页码:465 / 481
页数:17
相关论文
共 42 条
  • [1] ANALYSIS OF BILIRUBIN AND BILIRUBIN MONO-CONJUGATES AND DI-CONJUGATES - DETERMINATION OF THEIR RELATIVE AMOUNTS IN BIOLOGICAL SAMPLES
    BLANCKAERT, N
    [J]. BIOCHEMICAL JOURNAL, 1980, 185 (01) : 115 - 128
  • [2] Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans -: Evidence for involvement of cytochrome P450 3A4
    Bodin, K
    Bretillon, L
    Aden, Y
    Bertilsson, L
    Broomé, U
    Einarsson, C
    Diczfalusy, U
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (42) : 38685 - 38689
  • [3] Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats
    Bolder, U
    Trang, NV
    Hagey, LR
    Schteingart, CD
    Ton-Nu, HT
    Cerrè, C
    Elferink, RPJO
    Hofmann, AF
    [J]. GASTROENTEROLOGY, 1999, 117 (04) : 962 - 971
  • [4] DIFFERING EFFECTS OF NOR-URSODEOXYCHOLIC OR URSODEOXYCHOLIC ACID ON HEPATIC HISTOLOGY AND BILE-ACID METABOLISM IN THE RABBIT
    COHEN, BI
    HOFMANN, AF
    MOSBACH, EH
    STENGER, RJ
    ROTHSCHILD, MA
    HAGEY, LR
    YOON, YB
    [J]. GASTROENTEROLOGY, 1986, 91 (01) : 189 - 197
  • [5] Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles
    Fickert, P
    Zollner, G
    Fuchsbichler, A
    Stumptner, C
    Weiglein, AH
    Lammert, F
    Marschall, HU
    Tsybrovskyy, O
    Zatloukal, K
    Denk, H
    Trauner, M
    [J]. GASTROENTEROLOGY, 2002, 123 (04) : 1238 - 1251
  • [6] Oncosis represents the main type of cell death in mouse models of cholestasis
    Fickert, P
    Trauner, M
    Fuchsbichler, A
    Zollner, G
    Wagner, M
    Marschall, HU
    Zatloukal, K
    Denk, H
    [J]. JOURNAL OF HEPATOLOGY, 2005, 42 (03) : 378 - 385
  • [7] Regurgitation of bile acids from leaky sclerosing cholangitis in Mdr2 (Abcb4) bile ducts causes knockout mice
    Fickert, P
    Fuchsbichler, A
    Wagner, M
    Zollner, G
    Kaser, A
    Tilg, H
    Krause, R
    Lammert, F
    Langner, C
    Zatloukal, K
    Marschall, HU
    Denk, H
    Trauner, M
    [J]. GASTROENTEROLOGY, 2004, 127 (01) : 261 - 274
  • [8] Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins
    Fickert, P
    Trauner, M
    Fuchsbichler, A
    Stumptner, C
    Zatloukal, K
    Denk, H
    [J]. JOURNAL OF HEPATOLOGY, 2003, 38 (04) : 387 - 394
  • [9] Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver
    Fickert, P
    Zollner, G
    Fuchsbichler, A
    Stumptner, C
    Pojer, C
    Zenz, R
    Lammert, F
    Stieger, B
    Meier, PJ
    Zatloukal, K
    Denk, H
    Trauner, M
    [J]. GASTROENTEROLOGY, 2001, 121 (01) : 170 - 183
  • [10] Reduced oncotic necrosis in Fas receptor-deficient C57BL/6J-lpr mice after bile duct ligation
    Gujral, JS
    Liu, J
    Farhood, A
    Jaeschke, H
    [J]. HEPATOLOGY, 2004, 40 (04) : 998 - 1007